Tom T Karnezis1, Terence M Davidson. 1. Division of Otolaryngology-Head and Neck Surgery, University of California, San Diego School of Medicine, San Diego, California, USA.
Abstract
OBJECTIVE/HYPOTHESIS: Bevacizumab delivered as a submucosal and topical intranasal therapy effectively controls hereditary hemorrhagic telangiectasia (HHT)-associated epistaxis. STUDY DESIGN: Prospective institutional review board-approved study. METHODS: Between December 2009 and December 2010, 19 patients with HHT-associated epistaxis were treated with 100 mg of intranasal submucosal bevacizumab. Following treatment, patients were contacted monthly to report their epistaxis severity score (ESS) for 9 or more months after their initial treatment. If a patient had a significant increase in their ESS, they were offered treatment with 100 mg of topical bevacizumab, administered via a metered dose atomizer. All treatments were recorded. RESULTS: All 19 patients had a postinjection ESS documented through 9 months, whereas 17 patients had completed ESS data between months 10 and 12. Six of the 19 patients received eight additional 100 mg of topical bevacizumab treatments because they had an increase in their ESS. Results demonstrated a mean preinjection ESS of 8.12, with an ESS nadir of 2.00 reached at 2 months following submucosal injection (P < 0.0001). Over the following 12 months, the mean ESS steadily increased back to a maximum of 3.6 reached at 11 months following injection (P < .0001). CONCLUSIONS: Intranasal submucosal bevacizumab effectively treats HHT-associated epistaxis for up to 12 months following treatment.
OBJECTIVE/HYPOTHESIS: Bevacizumab delivered as a submucosal and topical intranasal therapy effectively controls hereditary hemorrhagic telangiectasia (HHT)-associated epistaxis. STUDY DESIGN: Prospective institutional review board-approved study. METHODS: Between December 2009 and December 2010, 19 patients with HHT-associated epistaxis were treated with 100 mg of intranasal submucosal bevacizumab. Following treatment, patients were contacted monthly to report their epistaxis severity score (ESS) for 9 or more months after their initial treatment. If a patient had a significant increase in their ESS, they were offered treatment with 100 mg of topical bevacizumab, administered via a metered dose atomizer. All treatments were recorded. RESULTS: All 19 patients had a postinjection ESS documented through 9 months, whereas 17 patients had completed ESS data between months 10 and 12. Six of the 19 patients received eight additional 100 mg of topical bevacizumab treatments because they had an increase in their ESS. Results demonstrated a mean preinjection ESS of 8.12, with an ESS nadir of 2.00 reached at 2 months following submucosal injection (P < 0.0001). Over the following 12 months, the mean ESS steadily increased back to a maximum of 3.6 reached at 11 months following injection (P < .0001). CONCLUSIONS: Intranasal submucosal bevacizumab effectively treats HHT-associated epistaxis for up to 12 months following treatment.
Authors: Chul Han; Se-Woon Choe; Yong Hwan Kim; Abhinav P Acharya; Benjamin G Keselowsky; Brian S Sorg; Young-Jae Lee; S Paul Oh Journal: Angiogenesis Date: 2014-06-24 Impact factor: 9.596
Authors: Vanessa F Schmidt; Max Masthoff; Veronika Vielsmeier; Caroline T Seebauer; Özlem Cangir; Lutz Meyer; Antje Mükke; Werner Lang; Axel Schmid; Peter B Sporns; Richard Brill; Walter A Wohlgemuth; Natascha Platz Batista da Silva; Max Seidensticker; Regina Schinner; Julia Küppers; Beate Häberle; Frank Haubner; Jens Ricke; Martin Zenker; Melanie A Kimm; Moritz Wildgruber Journal: Cardiovasc Intervent Radiol Date: 2022-10-19 Impact factor: 2.797